Das hepatozelluläre Karzinom: alternative Therapiestrategien

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist weltweit einer der häufigsten malignen Tumoren mit steigender Inzidenz auch in westlichen Ländern. Unbehandelt ist die Prognose außerordentlich ungünstig. Zur Therapie des HCCs stehen chirurgische und nicht-chirurgische Verfahren zur Verfügung. Resektion und in ausgewählten Fällen die Lebertransplantation sind die einzigen potenziell kurativen Therapieverfahren. Nicht-chirurgische Therapiemöglichkeiten sind lokal-interventionelle und transarterielle Verfahren. Eine Reihe von alternativen Therapiestrategien wie die medikamentöse Therapie mit antiangiogenetischen, antiproliferativen oder antiinflammatorischen Substanzen, Immuntherapeutika, gentherapeutische Ansätze und die interne bzw. externe Bestrahlung werden derzeit auf ihre Wirksamkeit untersucht, das Überleben bzw. das Rezidiv-freie Überleben der Patienten mit HCC zu verlängern. Diese Arbeit soll einen Überblick über die aktuellen alternativen Therapiemöglichkeiten beim HCC geben.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some areas of the world. The prognosis of HCC patients is generally very poor with a 5-year survival rate of less than 5 %. Therapeutic strategies include surgery (resection or liver transplantation) and non-surgical interventions, such as percutaneous ethanol injection or radiofrequency thermal ablation as well as transarterial embolization or chemoembolization. Therefore, the development and evaluation of novel HCC treatment strategies such as the use of antiangiogenic, antiproliferative or antiinflammatoric drugs, immune therapeuticals, gene therapy and internal or external radiation are of utmost importance. This review should give an overview of possible alternative therapies in HCC treatment.

hepatozelluläres Karzinom - Immuntherapie - Gentherapie - Antiangiogenese - medikamentöse Therapie

hepatocellular carcinoma - immune therapy - gene therapy - antiangiogenesis - drug therapy

Literatur

• 1 Abou-Alfa G K, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian N S, Feit K, Ackerman J, De Jager R L, Eckhardt S G, O'Reilly E M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.  J Clin Oncol. 2006;  24 4441-4447
• 2 Adams J, Palombella V J, Elliott P J. Proteasome inhibition: a new strategy in cancer treatment.  Invest New Drugs. 2000;  18 109-121
• 3 Becker G, Allgaier H P, Olschewski M, Zahringer A, Blum H E. HECTOR Study Group . Related Articles, Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.  Hepatology. 2007;  45 9-15
• 4 Bergsland E K. Molecular mechanisms underlying the development of hepatocellular carcinoma.  Semin Oncol. 2001;  28 521-531
• 5 Block A, Chen S H, Kosai K, Finegold M, Woo S L. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors.  Pancreas. 1997;  15 25-34
• 6 Blum H E. Molecular targets for prevention of hepatocellular carcinoma.  Dig Dis. 2002;  20 81-90
• 7 Bosch F X, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 S5-S16
• 8 Bruix J, Sherman M. Management of hepatocellular carcinoma.  Hepatology. 2005;  42 1208-1236
• 9 Butterfield L H, Koh A, Meng W, Vollmer C M, Ribas A, Dissette V, Lee E, Glaspy J A, McBride W H, Economou J S. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.  Cancer Res. 1999;  59 3134-3142
• 10 Butterfield L H, Meng W S, Koh A, Vollmer C M, Ribas A, Dissette V, Faull K, Glaspy J A, McBride W H, Economou J S. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.  J Immunol. 2001;  166 5300-5308
• 11 Butterfield L H, Ribas A, Dissette V B, Lee Y, Yang J Q, De la Rocha P, Duran S D, Hernandez J, Seja E, Potter D M, McBride W H, Finn R, Glaspy J A, Economou J S. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.  Clin Cancer Res. 2006;  12 2817-2825
• 12 Butterfield L H, Ribas A, Meng W S, Dissette V, Amarnani S, Vu H T, Seja E, Todd K, Glaspy J A, McBride W H, Economou J S. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.  Clin Cancer Res. 2003;  9 5902-5908
• 13 Cantz T, Ott M, Kubicka S, Manns M P. [Gene and immunotherapy of liver diseases].  Internist (Berl). 2001;  42 1357-1362 1364-1365
• 14 Caruso Y, Panis M, Gagandeep S, Houssin D, Salzmann J L, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.  Proc Natl Acad Sci USA. 1993;  90 7024-7028
• 15 Chenivesse X, Franco D, Brechot C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis.  J Hepatol. 1993;  18 168-172
• 16 El-Serag H B, Mason A C, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.  Hepatology. 2001;  33 62-65
• 17 Elba S, Giannuzzi V, Misciagna G, Manghisi O G. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.  Ital J Gastroenterol. 1994;  26 66-68
• 18 Engstrom P F, Levin B, Moertel C G, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma.  Cancer. 1990;  65 2641-2643
• 19 Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, Naccarato R. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen.  J Hepatol. 1990;  11 297-301
• 20 Fuchs C S, Clark J W, Ryan D P, Kulke M H, Kim H, Earle C C, Vincitore M, Mayer R J, Stuart K E. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.  Cancer. 2002;  94 3186-3191
• 21 Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, Nagano H, Umeshita K, Sakon M, Matsuura N, Nakamori S, Monden M. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.  Hepatology. 2001;  34 638-650
• 22 Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerniciolini R, Pierce J E, Hossfeld D K. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma.  Proc Am Soc Clin Oncol. 2004;  334 ,  (Abstract 4089)
• 23 Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation.  Int J Oncol. 1999;  14 453-460
• 24 Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara K, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto J, Hayashi N, Hori M. Activation of mitogen-activated protein kinases / extracellular signal-regulated kinases in human hepatocellular carcinoma.  Hepatology. 1998;  27 951-958
• 25 Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen C L, Kawano K, Kitano S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.  Cancer Immunol Immunother. 2003;  52 155-161
• 26 Jin-no K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Endo H, Doi T, Mandai K, Ishitsuka H. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.  Cancer. 1998;  82 1260-1267
• 27 Jung Y J, Lee K H, Choi D W, Han C J, Jeong S H, Kim K C, Oh J W, Park T K, Kim C M. Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma.  Cancer Lett. 2001;  168 57-63
• 28 Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos O N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.  Gut. 1998;  42 442-447
• 29 Kuang M, Peng B G, Lu M D, Liang L J, Huang J F, He Q, Hua Y P, Totsuka S, Liu S Q, Leong K W, Ohno T. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.  Clin Cancer Res. 2004;  10 1574-1579
• 30 Kubicka S, Rudolph K L, Tietze M K, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.  Hepatogastroenterology. 2001;  48 783-789
• 31 Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells.  J Gastroenterol Hepatol. 2002;  17 889-896
• 32 Lin D Y, Lin S M, Liaw Y F. Non-surgical treatment of hepatocellular carcinoma.  J Gastroenterol Hepatol. 1997;  12 S319-S328
• 33 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 1907-1917
• 34 LLovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J. for the SHARP investigators study group . Randomized phase III trial of sorafenib versus plazebo in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 18 S, LBA 1
• 35 Lozano R D, Patt T Z, Hassan M M. Oral capecitabine for the treatment of hepatobiliary cancers.  Proc Am Soc Clin Oncol. 2000;  264 ,  (Abstract 1025)
• 36 Luo G, Huang S, Xie X, Stockert E, Chen Y T, Kubuschok B, Pfreundschuh M. Expression of cancer-testis genes in human hepatocellular carcinomas.  Cancer Immun. 2002;  2 11
• 37 Lygidakis N J, Kosmidis P, Ziras N, Parissis J, Kyparidou E. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.  J Interferon Cytokine Res. 1995;  15 467-472
• 38 Martinez Cerezo F J, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, Martinez Nogueras A, Vilardell F. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma.  J Hepatol. 1994;  20 702-706
• 39 McKillop I H, Schmidt C M, Cahill P A, Sitzmann J V. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma.  Hepatology. 1997;  26 1484-1491
• 40 Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.  J Hepatol. 1997;  27 854-861
• 41 Murray C J, Lopez A D. Mortality by cause for eight regions of the world: Global Burden of Disease Study.  Lancet. 1997;  349 1269-1276
• 42 Nakamoto Y, Guidotti L G, Kuhlen C V, Fowler P, Chisari F V. Immune pathogenesis of hepatocellular carcinoma.  J Exp Med. 1998;  188 341-350
• 43 Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K, Kobayashi K, Suda T. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy.  J Exp Med. 2002;  196 1105-1111
• 44 Nowak A K, Stockler M R, Chow P K, Findlay M. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.  Cancer. 2005;  103 1408-1414
• 45 Ozturk M. Genetic aspects of hepatocellular carcinogenesis.  Semin Liver Dis. 1999;  19 235-242
• 46 Patt Y Z, Hassan M M, Lozano R D, Waugh K A, Hoque A M, Frome A I, Lahoti S, Ellis L, Vauthey J N, Curley S A, Schnirer L, Raijman I. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.  Clin Cancer Res. 2001;  7 3375-3380
• 47 Peng S Y, Chou S P, Hsu H C. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma.  J Hepatol. 1998;  29 281-289
• 48 Philip A, Mahoney M R, Allmer C, Thomas J, Pitot H C, Kim G, Donehower R C, Fitch T, Picus J, Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.  J Clin Oncol. 2005;  23 6657-6663
• 49 Rabe C, Pilz T, Allgaier H P, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann W H. [Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.].  Z Gastroenterol. 2002;  40 395-400
• 50 Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, Waldhoer T, Oberhuber G, Ferenci P, Gangl A, Mueller C. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma.  J Immunother. 2002;  25 489-499
• 51 Reubi J C, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas.  Gut. 1999;  45 766-774
• 52 Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil J C, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.  J Clin Oncol. 2004;  22 1389-1397
• 53 Schwartz J D, Schwartz M, Goldman J, Lehrer D, Coll D, Kinkabwala M, Wadler S. Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein.  Proc Am Soc Clin Oncol. 2005;  35 ,  (Abstract 134)
• 54 Shah M A, Kortnasky J Gonen M, Drobjnak M, Kenemy N, Saltz L B, Weyerbacher A, Lefkonitz R, Kelson D P, Schwartz G K. Mature results of a phase I study of irinotecan and Flavopirol: a clinically and biologically active regimen.  Proc Am Soc Clin Oncol. 2003;  262 ,  (Abstract 1051)
• 55 Simonetti R G, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.  Ann Oncol. 1997;  8 117-136
• 56 Soini Y, Virkajarvi N, Raunio H, Paakko P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.  J Clin Pathol. 1996;  49 470-473
• 57 Strumberg D, Richly H, Hilger R A, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase C G, Schwartz B, Awada A, Voigtmann R, Scheulen M E, Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.  J Clin Oncol. 2005;  23 965-972
• 58 Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma.  Cancer Res. 1996;  56 3004-3009
• 59 Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma.  Cancer. 1999;  85 1234-1240
• 60 Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T, Yamazaki S, Hasegawa H, Suzuki K, Yamagata M. Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report.  Cancer. 1991;  68 2391-2396
• 61 Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 802-807
• 62 Thomas M B, Dutta A, Brown T, Charnsangavej C, Rashid A, Hoff P M, Dancey J, Abbruzzese J L. Phase II open-label study of OS!-774 in unresectable hepatocellular carcinoma.  Proc Am Soc Clin Oncol. 2005;  321 ,  (Abstract 4038)
• 63 Thorgeirsson S S. Hunting for tumor suppressor genes in liver cancer.  Hepatology. 2003;  37 739-741
• 64 Yang T S, Lin Y C, Chen J S, Wang H M, Wang C H. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.  Cancer. 2000;  89 750-756
• 65 Yuen M F, Poon R T, Lai C L, Fan S T, Lo C M, Wong K W, Wong W M, Wong B C. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.  Hepatology. 2002;  36 687-691
• 66 Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, Cavallo C, Uggeri J, Scandroglio R, Crafa P, Spagnoli G C, Ferrari C, Missale G. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma.  J Hepatol. 2004;  40 102-109
• 67 Zhu A X, Sahani D, Norden-Zfoni N, Holalkere N S, Blaszkowsky L, Ryan D P, Clark J W, Taylor K, Heymach J V, Stuart K. A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma.  Proc Am Soc Clin Oncol. 2005;  331 , (Abstract 4120)